Beam Therapeutics (BEAM) stock is in focus after the FDA cleared its investigational new drug application for BEAM-304, an in vivo base editing therapy targeting phenylketonuria, a rare inherited metabolic disorder.

Beam Therapeutics shares trade at US$33.20 after a 1 day share price decline of 6.56%, while the 30 day share price return of 15.92% and 1 year total shareholder return of 93.59% point to momentum that has recently strengthened around BEAM-304 and other pipeline updates.

If this kind of gene editing progress has your attention, it could be a good moment to see what else is moving in healthcare focused AI, starting with our 38 healthcare AI stocks

With Beam Therapeutics now cleared to move BEAM-304 into the clinic and the stock up 93.59% over 1 year, the key question is whether investors are still underestimating its pipeline or if the market is already pricing in future growth.

Most Popular Narrative: 77.9% Undervalued

With Beam Therapeutics last closing at $33.20 against a narrative fair value of $150, the gap between market pricing and narrative expectations is striking and hard to ignore.

The investment thesis in Beam Therapeutics is a long-term, high-conviction bet on a fundamental technological shift in genetic medicine. While first-generation gene editors like CRISPR-Cas9 function as "molecular scissors," they are an inherently disruptive tool. By creating double-strand DNA breaks, they introduce significant risks, including unpredictable insertions, deletions, and large genomic rearrangements. Beam represents "Gene Editing 2.0". Its base editing platform is a "molecular pencil", a precision instrument that chemically rewrites a single "letter" of the genetic code without cutting the DNA backbone. This approach offers a potentially superior safety and precision profile, designed to mitigate the core risks that plague its predecessors.

This narrative leans heavily on Beam Therapeutics turning its base editing platform and liver programs into a long lasting cash generator, supported by ambitious revenue scales and healthy margins. Curious which clinical programs carry the most weight in that $150 fair value and how the projected economics stack across them.

Result: Fair Value of $150 (UNDERVALUED)

However, there are still clear pressure points for the Beam Therapeutics narrative, especially if future BEAM-302 data disappoints or if regulatory feedback on base editing becomes more cautious.

Next Steps

If the mixed sentiment around Beam Therapeutics has you thinking, now is the time to review the data yourself and weigh both sides of the story with 2 key rewards and 2 important warning signs

Looking for more Beam Therapeutics investment ideas?

If Beam Therapeutics has sharpened your focus on opportunities in the market, do not stop here, broaden your watchlist with other stocks that fit your style.

• Target potential value opportunities by scanning 44 high quality undervalued stocks that pair quality fundamentals with prices that may not fully reflect them.
• Strengthen your income playbook with 7 dividend fortresses designed for investors who want yield supported by more robust business profiles.
• Prioritise resilience by reviewing 67 resilient stocks with low risk scores that score well on stability, helping you avoid unnecessary surprises.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.